COWP yields 2000000.00% · ABBV yields 3.06%● Live data
📍 COWP pulled ahead of the other in Year 1
Combined, COWP + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of COWP + ABBV for your $10,000?
Canal Capital Corporation engages in real estate and stockyard operations in the United States. The company is involved in the development, management, and sale of its real estate properties. Its real estate properties comprise exchange buildings; land and structures leased to meat packing facilities, railcar repair shops, lumber yards, and various other commercial and retail businesses; and vacant land for development or resale. The company has real estate properties in Sioux City, Iowa; South St Paul, Minnesota; St Joseph, Missouri; and Omaha, Nebraska. As of October 31, 2011, it owned approximately 2 acres of undeveloped land in Sioux City, Iowa. The company also operates a central public stockyard located in St. Joseph, Missouri. Its stockyard provides various services and facilities required to operate an independent market for the sale of livestock, including veterinary facilities, auction arenas, auctioneers, weigh masters and scales, feed and bedding facilities, and security personnel, as well as offers other services, such as pure bred and other specialty sales for producer organizations. In addition, the company sells its antiquities through independent art dealers and at public art auctions. Canal Capital Corporation was founded in 1964 and is headquartered in Port Jefferson Station, New York.
Full COWP Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.